Magnesium Sulfate



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 17.6%
Spinal Anaesthesia 16.0%
Pre-eclampsia 12.8%
Asthma 8.0%
Eclampsia 7.2%
Convulsion 4.8%
General Anaesthesia 4.8%
Premature Labour 4.8%
Tocolysis 4.8%
Dialysis 3.2%
Hypomagnesaemia 2.4%
Mechanical Ventilation 2.4%
Sedation 2.4%
Blood Magnesium Decreased 1.6%
Constipation 1.6%
Maternal Therapy To Enhance Foetal Lung Maturity 1.6%
Ventricular Tachycardia 1.6%
Analgesic Therapy 0.8%
Bacterial Toxaemia 0.8%
Blood Magnesium Abnormal 0.8%
Medication Error 13.5%
Pulmonary Interstitial Emphysema Syndrome 12.2%
Procedural Hypotension 8.1%
Rib Fracture 8.1%
Hypotension 5.4%
Wrong Drug Administered 5.4%
Convulsion 4.1%
Foetal Death 4.1%
Osteopenia 4.1%
Premature Baby 4.1%
Respiratory Disorder Neonatal 4.1%
Unresponsive To Stimuli 4.1%
Urine Output Decreased 4.1%
Bradycardia 2.7%
Drug Exposure During Pregnancy 2.7%
Hypermagnesaemia 2.7%
Incorrect Dose Administered 2.7%
Incorrect Drug Administration Rate 2.7%
Infusion Related Reaction 2.7%
Movement Disorder 2.7%
Secondary
Drug Use For Unknown Indication 20.3%
Asthma 13.7%
Product Used For Unknown Indication 11.0%
Hypertension 8.2%
Parenteral Nutrition 7.7%
Status Asthmaticus 3.8%
Prophylaxis 3.5%
Pain 3.4%
Drug Exposure During Pregnancy 2.9%
Premedication 2.9%
Rectal Cancer 2.9%
Adverse Drug Reaction 2.7%
Pre-eclampsia 2.6%
Ventricular Tachycardia 2.5%
Colon Cancer 2.3%
Nausea 2.0%
Constipation 1.9%
Drug Therapy 1.9%
Gastrointestinal Disorder 1.9%
Ill-defined Disorder 1.7%
Tachycardia Foetal 12.0%
Drug Ineffective 9.8%
Toxic Epidermal Necrolysis 9.8%
Grand Mal Convulsion 7.5%
Premature Baby 7.5%
Oxygen Saturation Decreased 6.8%
Neuromuscular Blockade 6.0%
Tremor 4.5%
Respiratory Failure 3.8%
Unresponsive To Stimuli 3.8%
Ventricular Tachycardia 3.8%
Anaphylactic Reaction 3.0%
Completed Suicide 3.0%
Death 3.0%
Hyperhidrosis 3.0%
Medication Error 3.0%
Pulmonary Oedema 3.0%
Cardiac Arrest 2.3%
Creutzfeldt-jakob Disease 2.3%
Disseminated Intravascular Coagulation 2.3%
Concomitant
Product Used For Unknown Indication 38.8%
Drug Use For Unknown Indication 24.9%
Prophylaxis 7.7%
Hypertension 4.3%
Pain 3.7%
Nausea 2.4%
Constipation 2.3%
Multiple Myeloma 1.9%
Premedication 1.9%
Adverse Event 1.4%
Depression 1.3%
Colorectal Cancer 1.3%
Insomnia 1.2%
Non-small Cell Lung Cancer 1.1%
Acute Myeloid Leukaemia 1.1%
Coronary Artery Bypass 1.0%
Prophylaxis Of Nausea And Vomiting 0.9%
Diabetes Mellitus 0.9%
Gastrooesophageal Reflux Disease 0.9%
Asthma 0.9%
Vomiting 13.4%
Thrombocytopenia 6.3%
Sepsis 6.2%
Weight Decreased 6.0%
White Blood Cell Count Decreased 5.7%
Pneumonia 5.4%
Pain 5.2%
Weight Increased 5.1%
Renal Failure Acute 4.9%
Renal Failure 4.4%
Pyrexia 4.3%
Death 4.0%
Interstitial Lung Disease 4.0%
Nausea 4.0%
Injury 3.6%
Rash 3.6%
Respiratory Failure 3.6%
Toxic Epidermal Necrolysis 3.5%
Ventricular Septal Defect 3.5%
Fear 3.4%
Interacting
Hypertension 15.2%
Maternal Exposure During Pregnancy 15.2%
Ill-defined Disorder 12.1%
Local Anaesthesia 12.1%
Pre-eclampsia 9.1%
Anxiety 7.6%
Foetal Exposure During Pregnancy 7.6%
Drug Use For Unknown Indication 6.1%
Product Used For Unknown Indication 6.1%
Chorioretinitis 3.0%
Labour Pain 3.0%
Proteinuria 3.0%
Neuromuscular Blockade 23.5%
Tachycardia 23.5%
Drug Interaction 11.8%
Meniscus Operation 11.8%
Unresponsive To Stimuli 11.8%
Apgar Score Low 5.9%
Foetal Heart Rate Abnormal 5.9%
Injection Site Pain 5.9%